Aurisco Pharmaceutical Co Ltd 605116.SS

Last Updated: May 15, 12:00 AM·SSE

Aurisco Pharmaceutical Co Ltd

Aurisco Pharmaceutical Co Ltd. Stock Analysis 605116.SS

China Health Care Small Cap
Aurisco Pharmaceutical Co., Ltd. engages in the development and production of pharmaceutical chemicals. The company is headquartered in Taizhou, Zhejiang and currently employs 2,026 full-time employees. The company went IPO on 2020-09-21. The firm's APIs and intermediates are mainly respiratory, cardiovascular, anti-infection, nervous system, anti-tumor and women's health products, including flumethasone, fluticasone propionate, eplerenone, tenofovir, pregabalin and other APIs and intermediates. The firm sells products in the domestic market and overseas markets.
Read More
Lock image
crown-icon

Shariah Compliance Report

An extensive business and financial screening of the company which specifies why a stock is halal or haram!

Disclaimer

The content provided on this website is intended solely for informational and educational purposes. Musaffa is a technology, data, education, and research company. We are not licensed financial service provider by the authorized relevant financial service regulator in India or any other regulatory government body, and we do not offer or facilitate any trading, brokerage, investment, or financial advisory services. We do not deliberately target an audience seeking financial services.

By accessing this website, you acknowledge and confirm that you are seeking information relating to Musaffa of your own accord, and that there has been no form of solicitation, advertisement, or inducement by Musaffa or its members. Musaffa shall not be liable for the consequences of any action taken by relying on the material or information provided on this website. The contents of this website are the intellectual property of Musaffa.